| Bioactivity | Frunevetmab (NV-02) is a felinized anti-nerve growth factor (NGF) monoclonal antibody with a Kd of 20 pM. Frunevetmab can effectively decrease osteoarthritis (OA) pain in cats[1][2]. |
| Target | Kd: 20 pM (NGF) |
| Invitro | Frunevetmab (NV-02) neutralizes NGF with high affinity and potency and does not bind complement[2]. |
| In Vivo | Frunevetmab (1.0-2.8 mg/kg; s.c; on days 0, 28, and 56) shows positive treatment effects in cats with naturally-occurring OA pain and associated mobility impairment and disability[1]. Animal Model: |
| Name | Frunevetmab |
| CAS | 1708936-80-4 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Margaret E Gruen, et al. Frunevetmab, a felinized anti-nerve growth factor monoclonal antibody, for the treatment of pain from osteoarthritis in cats. J Vet Intern Med. 2021 Nov;35(6):2752-2762. [2]. D P Gearing, et al. In Vitro and In Vivo Characterization of a Fully Felinized Therapeutic Anti-Nerve Growth Factor Monoclonal Antibody for the Treatment of Pain in Cats. J Vet Intern Med. 2016 Jul;30(4):1129-37. |